Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-08-06

Clinical Trial Update: A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707) [Phase 3]

View source ↗

Summary

Phase 3 double-blind trial evaluating esmirtazapine (Org 50081) for efficacy and safety in insomnia; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • esmirtazapine (Org 50081) (esmirtazapine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Insomnia | Phase 3 | Status: COMPLETED | Results posted: 2014-08-06